Department of Pulmonary Medicine and Oncology, Graduate School of Medicine, Nippon Medical School, 1-1-5 Sendagi, Bunkyo-ku, Tokyo, 113-8603, Japan.
Respiratory Care Clinic Tokyo, Institute of Clinical Respirology, 1-12-5-1F, Kyobashi, Chuo-ku, Tokyo, 104-0031, Japan.
BMC Pulm Med. 2024 Nov 29;24(1):593. doi: 10.1186/s12890-024-03407-w.
Cardiovascular disease is a common comorbidity in chronic obstructive pulmonary disease (COPD) and pre-COPD patients, contributing significantly to morbidity and mortality. We aimed to investigate whether Galectin-3 (Gal-3) levels correlate with cardiovascular biomarkers and cardiopulmonary function in COPD and pre-COPD patients to assess its potential role as a marker for cardiovascular comorbidity.
Community-dwelling adults with and without COPD were recruited. Biomarkers including Gal-3, high-sensitivity cardiac troponin T (hs-cTnT), and N-terminal pro-brain natriuretic peptide (NT-proBNP) were measured. Subjects underwent pulmonary function tests, chest CT, echocardiograms, and a 6-minute walking test. The relationships between biomarkers and cardiopulmonary function were examined.
Among 120 subjects (97 COPD, 23 pre-COPD), the mean age was 70.2 years, and the mean predicted forced expiratory volume in 1 s (FEV1%) was 68.5%. Gal-3 levels averaged 1733.7 pg/mL. Gal-3 significantly correlated with NT-proBNP (ρ = 0.229, p = 0.012) and negatively with maximal pulse rate during the 6-minute walking test (ρ=-0.185, p = 0.043). No significant correlation was found between Gal-3 and hs-cTnT levels. However, hs-cTnT levels showed significant negative correlations with age (ρ=-0.526, p < 0.001), FEV1% (ρ=-0.373, p < 0.001), E/A ratio (ρ=-0.390, p < 0.001), and walking distance (ρ=-0.444, p < 0.001), and positive correlations with deceleration time (ρ = 0.299, p = 0.001), right ventricular systolic pressure (ρ = 0.197, p = 0.037), and high-sensitivity C-reactive protein (ρ = 0.212, p = 0.020).
Gal-3 levels show correlations with NT-proBNP and maximal pulse rate, supporting its investigation as a potential marker for cardiovascular comorbidity in COPD and pre-COPD populations.
心血管疾病是慢性阻塞性肺疾病（COPD）和 COPD 前患者的常见合并症，显著增加了发病率和死亡率。我们旨在研究 Galectin-3（Gal-3）水平是否与 COPD 和 COPD 前患者的心血管生物标志物和心肺功能相关，以评估其作为心血管合并症标志物的潜在作用。
招募了有和没有 COPD 的社区居住成年人。测量了生物标志物，包括 Gal-3、高敏心肌肌钙蛋白 T（hs-cTnT）和 N 端脑利钠肽前体（NT-proBNP）。受试者进行了肺功能测试、胸部 CT、超声心动图和 6 分钟步行测试。检查了生物标志物与心肺功能之间的关系。
在 120 名受试者（97 名 COPD，23 名 COPD 前）中，平均年龄为 70.2 岁，预计用力呼气量 1 秒率（FEV1%）平均为 68.5%。Gal-3 水平平均为 1733.7pg/ml。Gal-3 与 NT-proBNP 显著相关（ρ=0.229，p=0.012），与 6 分钟步行试验期间的最大脉搏率呈负相关（ρ=-0.185，p=0.043）。Gal-3 与 hs-cTnT 水平之间未发现显著相关性。然而，hs-cTnT 水平与年龄（ρ=-0.526，p<0.001）、FEV1%（ρ=-0.373，p<0.001）、E/A 比值（ρ=-0.390，p<0.001）和步行距离（ρ=-0.444，p<0.001）呈显著负相关，与减速时间（ρ=0.299，p=0.001）、右心室收缩压（ρ=0.197，p=0.037）和高敏 C 反应蛋白（ρ=0.212，p=0.020）呈显著正相关。
Gal-3 水平与 NT-proBNP 和最大脉搏率相关，支持将其作为 COPD 和 COPD 前人群心血管合并症的潜在标志物进行研究。
